Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 4/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | FYN | P06241 | 2/20 | 0.33 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | GMNN | O75496 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3231091 | 0.77 | ALDH1A1 (0.43) | ALOX15HSD17B10ALDH1A1EGFRCA2 | |
| SCHEMBL16719882 | 0.76 | ALDH1A1 (0.37) | ALOX15HSD17B10ALDH1A1EGFRCA2 | |
| SCHEMBL82438 | 0.74 | TDP1 (0.34) | ALDH1A1CA2LMNATDP1POLB | |
| SCHEMBL5314612 | 0.74 | CYP3A4 (0.41) | ALOX15HSD17B10ALDH1A1HPGDTDP1 | |
| SCHEMBL81364 | 0.74 | — | — | |
| SCHEMBL15638061 | 0.74 | ALDH1A1 (0.38) | ALOX15HSD17B10ALDH1A1HPGDTDP1 | |
| SCHEMBL16719734 | 0.74 | ALDH1A1 (0.35) | ALOX15HSD17B10ALDH1A1EGFRCA2 | |
| SCHEMBL225527 | 0.73 | TSHR (0.33) | LMNATSHR | |
| SCHEMBL456604 | 0.73 | ACHE (0.33) | TDP1CYP3A4TSHRTRPA1ATM | |
| SCHEMBL6591152 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104168958-A | Diaryl sulfonamides useful for the treatment of inflammation and cancer | KANCERA AB | 2014-11-26 | — | — | CN | claimed |
| EP-2900645-B1 | HERBICIDAL AND FUNGICIDAL 3-PHENYLISOXAZOLIN DERIVATIVES | BAYER CROPSCIENCE AG (DE) | 2019-08-21 | — | — | EP | disclosed |
| US-9585392-B2 | 3-phenylisoxazolin derivatives with herbicidal action | BAYER CROPSCIENCE AG (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | BAYER CROPSCIENCE AG (DE) | 2015-09-03 | — | — | US | disclosed |
| EP-2900645-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | Bayer CropScience AG (DE) | 2015-08-05 | — | — | EP | disclosed |
| CN-104168958-A | Diaryl sulfonamides useful for the treatment of inflammation and cancer | KANCERA AB | 2014-11-26 | — | — | CN | disclosed |
| CN-102438990-B | Substituted 2-acetamido-5-aryl-1, 2, 4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-08-20 | — | — | CN | disclosed |
| CN-103864704-A | Substituted 2-acetamido-5-aryl-1,2,4-triazolones and use thereof | BAYER SCHERING PHARMA AG | 2014-06-18 | — | — | CN | disclosed |
| WO-2010146351-A1 | INDOLYLMETHYL-MORPHOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-12-23 | — | — | WO | disclosed |
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| CN-1291979-C | Imidazole compounds and their use as adenosine deaminase inhibitors | JUJISAWA PHARAMCEUTICAL CO LTD (JP) | 2006-12-27 | — | — | CN | disclosed |
| CN-1319095-A | Imidazole compounds and their use as adenosine deaminase inhibitors | JUJISAWA PHARAMCEUTICAL CO LTD (JP) | 2001-10-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | ALOX15 1583/4885HSD17B10 3785/4885ALDH1A1 2646/4885 |
| US-20150245615-A1 | 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION | CYP4X1, CBR3, PAOX | ALOX15 3613/4885HSD17B10 708/4885ALDH1A1 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.